ArticleCancer research2016
Cell Adhesion Molecule CD166 Drives Malignant Progression and Osteolytic Disease in Multiple Myeloma.
Article in Cancer research, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 1 synthesis or guideline pooled it, 34 citations in OpenAlex.
- Meta-analysis indicating that high ALCAM expression predicts poor prognosis in colorectal cancer.Oncotarget · 2017Pooled it
- Rho-related GTP-binding protein RhoE (RND3) regulates multiple myeloma bone disease.Cancer cell international · 2026Article
- Precision radiolabeled B-cell maturation nanobody for targeted PET imaging and radioligand therapy of disseminated multiple myeloma.Theranostics · 2026Article
- Database analysis reveals endophilin A expression as a marker of metastasis and prognosis in breast cancer.Discover oncology · 2025Article
- LGR4 promotes proliferation and homing via activation of the NF‑κB signaling pathway in multiple myeloma.International journal of oncology · 2025Article
- Nanomaterials targeting cancer stem cells to overcome drug resistance and tumor recurrence.Frontiers in oncology · 2025Review
- Osteomacs promote maintenance of murine hematopoiesis through megakaryocyte-induced upregulation of Embigin and CD166.Stem cell reports · 2024Article
- The Human Soluble NKG2D Ligand Differentially Impacts Tumorigenicity and Progression in Temporal and Model-Dependent Modes.Biomedicines · 2024Article
- The influence of antibody CD166 on the treatment of tumor and the immunological mechanism in mice bearing oral squamous cell carcinoma.Translational cancer research · 2023Article
- Expression of integrin β-7 is epigenetically enhanced in multiple myeloma subgroups with high-risk cytogenetics.Clinical epigenetics · 2023Article
- CST6 suppresses osteolytic bone disease in multiple myeloma by blocking osteoclast differentiation.The Journal of clinical investigation · 2022Article
- Adhesion molecules in multiple myeloma oncogenesis and targeted therapy.International journal of hematologic oncology · 2022Review
- ALCAM-EGFR interaction regulates myelomagenesis.Blood advances · 2021Article
- The Clinical and Theranostic Values of Activated Leukocyte Cell Adhesion Molecule (ALCAM)/CD166 in Human Solid Cancers.Cancers · 2021Review
- Animal Models of Multiple Myeloma Bone Disease.Frontiers in genetics · 2021Review
- Discovery and validation of surfaceJournal for immunotherapy of cancer · 2020Article
- Plasmacytoma in patients with multiple myeloma: morphology and immunohistochemistry.BMC cancer · 2020Article
- A Comparison of Osteoblast and Osteoclast In Vitro Co-Culture Models and Their Translation for Preclinical Drug Testing Applications.International journal of molecular sciences · 2020Review
- CD166 Engagement Augments Mouse and Human Hematopoietic Progenitor Function via Activation of Stemness and Cell Cycle Pathways.Stem cells (Dayton, Ohio) · 2019Article
- BTK induces CAM-DR through regulation of CXCR4 degradation in multiple myeloma.American journal of translational research · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors at 2 institutions in 1 country.
Funding
Abstract
Multiple myeloma is incurable once osteolytic lesions have seeded at skeletal sites, but factors mediating this deadly pathogenic advance remain poorly understood. Here, we report evidence of a major role for the cell adhesion molecule CD166, which we discovered to be highly expressed in multiple myeloma cell lines and primary bone marrow cells from patients. CD166
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.